Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract

Fig. 2

Receiver operating characteristic (ROC) curves for SHOX2, SEPT9, and the combined biomarker panel (based on the sum of PMR values) in tissue specimens. The ROC curves and resulting area under the curve (AUC) values are depicted for a all 55 BTC specimens: AUC—SHOX2 = 0.918 [95% CI 0.865–0.971]; AUC—SEPT9 = 0.601 [95% CI 0.488–0.713]; AUC—Panel 0.933 [95% CI 0.886–0.979] b 43 CC specimens: AUC—SHOX2 = 09.21 [0.863–0.979]; AUC—SEPT9 = 0,.541 [95% CI 0.416–0.666]; AUC—Panel = 0.932 [95% CI 0.880–0.984] and c 12 GBC specimens: AUC—SHOX2 = 0.907 [95% CI 0.808–1.005]; AUC—SEPT9 = 0.815 [95% CI 0.637–0.993]; AUC—Panel = 0.935 [95% CI 0.855–1.015], respectively

Back to article page